Pancreatic cancer is a highly treatment resistant disease. We have developed a novel patient tumorgraft technology to improve therapy for this disease.Methods
Pancreatic cancer patient tumor specimens were initially established in NOD/SCID mice. The tumors were then passaged orthotopically into transgenic nude mice ubiquitously expressing GFP and subsequently to nude mice ubiquitously expressing RFP. The pancreatic cancer patient tumors, with very bright GFP and RFP stroma, were then orthotopically passaged to non-colored nude mice where they underwent fluorescence imaging with the FluorVivo instrument.Results
The patient tumors stably acquired brightly fluorescent stroma from the transgenic GFP and RFP nude mice. Upon orthotopic transplantation to the pancreas of non-transgenic nude mice, the brightly fluorescent patient tumors could be non-invasively imaged longitudinally as they grew on the pancreas in the non-colored nude mice.Conclusions
This non-invasively imageable tumor-graft model will be valuable for rapid screening for effective treatment options for individual pancreatic cancer patients, as well as for discovery of improved agents for this treatment-resistant disease.